Investigators are planning a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a novel neuroprotective medication for acute ischemic stroke. The primary outcome is the total volume of cerebral infarction at 90 days. During the design phase, the steering committee modifies the study protocol. Instead of estimating infarct volume using standard non-contrast computed tomography (CT), which has substantial inter-reader variability, the study will now utilize high-resolution magnetic resonance imaging (MRI) with an automated volumetric analysis algorithm. This change significantly improves measurement precision and reduces outcome variance. The anticipated true difference in mean infarct volume between the groups (effect size), the total number of enrolled patients, and the predefined significance level () remain unchanged. Which of the following best describes the expected statistical impact of this protocol modification?
- Decreases the probability of making a Type II error and increases statistical powerAnswer
- BDecreases the probability of making a Type I error and increases statistical power
- CIncreases the probability of making a Type II error and decreases statistical power
- DDecreases statistical power but eliminates the risk of confounding bias
- EHas no impact on statistical power but improves the external validity of the study results